Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Gurusamy, Kurinchi Selvan ^a   Ramamoorthy, Rajarajan ^a   Sharma, Dinesh ^a   Davidson, Brian R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTHRALGIA; BILE LEAKAGE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CRYOABLATION; DIARRHEA; EMBASE; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; LIVER ABSCESS; LIVER METASTASIS; LIVER RESECTION; MEDLINE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; QUALITY OF LIFE; QUASI EXPERIMENTAL STUDY; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; REVIEW; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; WOUND DEHISCENCE; WOUND INFECTION;

EID: 70349146311     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007060.pub2     Document Type: Review

References (46)

1. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars in Nuclear Medicine 2002;32(2):123-132
2. Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, et al.Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001;130(6):954-962 (Pubitemid 34014560)
3. Clark OA, Castro AA. Searching the Literatura Latino Americana e do Caribe em Ciencias da Saude (LILACS) database improves systematic reviews. International Journal of Epidemiology 2002;31(1):112-114
4. Coppa J, Pulvirenti A, Schiavo M, Romito R, Collini P, Di Bartolomeo M, et al.Resection versus transplantation for liver metastases from neuroendocrine tumors. Transplantation Proceedings 2001;33(1-2):1537-1539 (Pubitemid 32237966)
5. Curley SA. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Annals of Surgical Oncology 2008;15(1):11-13
6. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-350
7. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-188
8. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629-634 (Pubitemid 27387172)
9. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al.Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 2003;21(14):2689-2696 (Pubitemid 46606312)
10. Falconi M, Bassi C, Bonora A, Sartori N, Procacci C, Talamini G, et al.Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumours. Digestive Surgery 1999;16(1):32-38 (Pubitemid 29082416)
11. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al.Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92(5):1101-1107 (Pubitemid 32861657)
12. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al.Liver transplantation for neuroendocrine tumors. Journal of Gastrointestinal Surgery 2004;8(2):208-212
13. Garrean S, Hering J, Helton WS, Espat NJ. A primer on transarterial, chemical, and thermal ablative therapies for hepatic tumors. American Journal of Surgery 2007;194(1):79-88. (Pubitemid 46874356)
14. Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als-Nielsen B, et al.Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008, Issue 3. Art. No.: LIVER.
15. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al.Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104(8):1590-1602 (Pubitemid 41437421)
16. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-1558
17. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention 5.0.0 [updated February 2008]. The Cochrane Colloboration, 2008. Available from www.cochrane-handbook.org.
18. Ito H, Perez A, Brooks DC, Osteen RT, Zinner MJ, Moore FD Jr, et al.Surgical treatment of small bowel cancer: a 20-year single institution experience. Journal of Gastrointestinal Surgery 2003;7(7):925-930 (Pubitemid 37338560)
19. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-989 (Pubitemid 33131619)
20. Kölby L, Persson G, Franzén S, Ahrén B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. The British Journal of Surgery 2003;90:687-693 (Pubitemid 36760596)
21. Landry CS, Scoggins CR, McMasters KM, Martin RC 2nd. Management of hepatic metastasis of gastrointestinal carcinoid tumors. Journal of Surgical Oncology 2008;97(3):253-258 [PUBMED: 18264984]
22. Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pelissier S, Evrard S. Comparison of hepatic recurrences after resection or intra-operative radiofrequency ablation indicated by size and topographical characteristics of the metastases. European Journal of Surgical Oncology 2008;34(2):185-190 Epub 2007 Nov 12.
23. Leotlela PD, Jauch A, Holtgreve-Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocrine-related Cancer 2003;10(4):437-450
24. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Statistics in Medicine 2001;20(4):641-654 (Pubitemid 32166424)
25. Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007;142(1):10-19 (Pubitemid 47042092)
26. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97(4):934-959 [PUBMED: 12569593] (Pubitemid 36173145)
27. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-613 (Pubitemid 28380142)
28. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al.Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical Endocrinology 2001;55(1):47-60. (Pubitemid 34204299)
29. NCBI. MeSH database. http://www.ncbi.nlm.nih.gov/sites/entrez?db=mesh (last accessed on 2 September 2008).
30. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. International Journal of Epidemiology 1992;21(5):837-841
31. Nguyen C, Faraggi M, Giraudet AL, de Labriolle-Vaylet C, Aparicio T, Rouzet F, et al.Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. Journal of Nuclear Medicine 2004;45(10):1660-1668 (Pubitemid 47618472)
32. Oberg K, Norheim I, Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozocin plus 5-FU and human leukocyte interferon. European Journal of Cancer & Clinical Oncology 1989;25(10):1475-1479 (Pubitemid 19247456)
33. Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004;136(6):1218-1226 (Pubitemid 39647537)
34. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
35. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603. (Pubitemid 38405633)
36. Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al.Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology 1999;17(2):600-606 (Pubitemid 29075248)
37. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 2003;197(1):29-37. (Pubitemid 36759176)
38. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-412
39. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 2005;23(22):4897-4904 (Pubitemid 46223995)
40. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Archives of Surgery 2006;141(2):181-190 (Pubitemid 43276571)
41. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Statistics in Medicine 2004;23(9):1351-1375
42. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, et al.Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World Journal of Surgery 1996;20(7):892-899 (Pubitemid 26281920)
43. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Annals of Surgical Oncology 2000;7(8):593-600. (Pubitemid 30708482)
44. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al.Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-605
45. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al.Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130(4):677-685 (Pubitemid 32964613)
46. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. The Oncologist 2005;10(2):123-131 (Pubitemid 40261951)